Cargando…
An agent-based model of prostate Cancer bone metastasis progression and response to Radium223
BACKGROUND: Bone metastasis is the most frequent complication in prostate cancer patients and associated outcome remains fatal. Radium223 (Rad223), a bone targeting radioisotope improves overall survival in patients (3.6 months vs. placebo). However, clinical response is often followed by relapse an...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325060/ https://www.ncbi.nlm.nih.gov/pubmed/32600282 http://dx.doi.org/10.1186/s12885-020-07084-w |